Healthcare is outperforming the S&P 500 by more than 12 percentage points over the past four weeks. Regeneron is one of the clearest reasons why.
Why This Stock Now
Investors rotating away from AI hardware and software need somewhere to put the proceeds. Healthcare, alongside energy, is absorbing the most institutional capital. Regeneron has earned that attention: its Q3 2026 results delivered the kind of earnings acceleration that makes a stock a rotation destination rather than a refuge. The stock sat at a 52-week low of $591.52 on June 2, 2026. It recently touched $991.73. The business did not change. The recognition of it did.
The Business
Regeneron is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. Its commercial engine runs on three franchises. DUPIXENT, a biologic treatment for asthma, atopic dermatitis, and other inflammatory conditions, is the global growth driver. EYLEA HD is the company’s higher-dose retinal disease treatment, gaining share as the standard EYLEA faces biosimilar competition. LIBTAYO is a checkpoint inhibitor in oncology gaining expanded indications.
All three hit new all-time net sales records in Q3. The business does not rely on a single drug.
Why Wall Street Is Paying Attention
The Q3 results, reported October 30, were the clearest evidence yet that the Sanofi collaboration restructuring is paying off. For the first time, Regeneron recorded its full share of DUPIXENT collaboration profits after the Sanofi development balance was completely repaid. That structural shift drove a sharp step-up in Sanofi collaboration revenue, which rose to about $2.575 billion from about $1.456 billion a year earlier. Total revenue rose 36% year-over-year to $5.12 billion, ahead of consensus revenue expectations by roughly 10% to 12% based on widely cited estimates at the time.
Non-GAAP EPS of $20.07 beat the $16.08 consensus by 24.8%, and surged 70% from $11.83 a year earlier. Free cash flow through the first nine months of 2026 reached $2.9 billion. The company ended the quarter with $16.2 billion in cash and marketable securities, net of debt. CFO Christopher Fenimore called it the company’s third consecutive quarter of double-digit growth on both the top and bottom lines.
What’s Driving the Opportunity
The pipeline is where the upside is still not fully reflected. Regeneron has a November PDUFA date for cemdisiran, an RNA interference therapy for generalized myasthenia gravis, a Priority Review designation in hand. If approved, cemdisiran would be the first siRNA therapy for the disease and would expand Regeneron’s reach into neurology at scale.
Separately, interim CIDEB siRNA data for metabolic liver disease showed an approximately 70% average reduction in liver fat in 12 weeks, with the company planning to initiate a Phase 3 study in MASH/MASLD in Q4 2026. And ubamatamab, a bispecific antibody for ovarian cancer, remains an important oncology program, with Regeneron highlighting ongoing late-stage plans and follow-on trial work. Regeneron has also said it is on pace to initiate more than 15 Phase 3 trials this year. For a company already generating nearly $20 billion in annualized revenue, that is not a pipeline built for a Hail Mary. It is an extension of a proven commercial and scientific machine.
Wall Street’s forward P/E on the stock is commonly quoted in the low-teens. At current prices near $952, the stock trades about 4% below its 52-week high, and the average consensus price target is around $985.
What Could Go Wrong
FDA decisions on complex biologics carry binary risk. A cemdisiran rejection would remove the nearest-term pipeline catalyst and likely reset the stock. Meanwhile, legacy EYLEA biosimilar competition is a real revenue headwind. Regeneron has managed it with EYLEA HD, but if the transition stalls, the top line faces pressure.
Insider sales have been modest but present in recent weeks, and R&D expense is guided to grow at a mid-teens rate in 2027, which will compress near-term margins even as revenue grows. The stock is not cheap in absolute terms.
The Bottom Line
Regeneron is not a speculative biotech. It has $16 billion in net cash, three drugs at all-time sales records, and a pipeline deep enough that the next catalyst is always visible. The Q3 beat of 24% on earnings is not a one-quarter accident. It reflects a structural step-up in profitability now that the Sanofi development balance is behind it. Healthcare is leading the market. Within healthcare, Regeneron is leading the fundamentals. That combination narrows the field considerably.
